{
    "clinical_study": {
        "@rank": "100931", 
        "arm_group": {
            "arm_group_label": "ANG1005", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells\n      in HER2+ breast cancer patients with recurrent brain metastases."
        }, 
        "brief_title": "ANG1005 in HER2+ Breast Cancer Patients With Progressive/Recurrent Brain Metastases", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Brain Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "See above."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u2265 18 years old\n\n          2. Documented HER2+ breast cancer\n\n          3. Recurrent/progressing brain metastases from breast cancer\n\n          4. At least one radiologically-confirmed and measurable metastatic brain lesion -5.\n             Prior treatment with whole brain radiotherapy (WBRT)\n\n        6. Neurologically stable 7. Karnofsky Performance Status (KPS) score \u2265 80\n\n        Exclusion Criteria:\n\n          1. Known leptomeningeal disease\n\n          2. Prior treatment with ANG1005/GRN1005\n\n          3. Pregnancy or lactation\n\n          4. Inadequate bone marrow reserve\n\n          5. Any evidence of severe or uncontrolled diseases\n\n          6. Patients with the presence of an infection including abscess or fistulae, or known\n             infection with hepatitis B or C or HIV\n\n          7. CNS disease requiring immediate neurosurgery intervention (e.g., resection, shunt\n             placement, etc.)\n\n          8. Known allergy to paclitaxel or any of its components"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048059", 
            "org_study_id": "ANG1005-CLN-04"
        }, 
        "intervention": {
            "arm_group_label": "ANG1005", 
            "intervention_name": "ANG1005", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ANG1005", 
            "GRN1005", 
            "LRP-1", 
            "Targeted therapy", 
            "Breast cancer", 
            "Brain metastases", 
            "Brain tumor", 
            "Blood-brain barrier", 
            "Trastuzumab", 
            "Herceptin", 
            "Paclitaxel", 
            "Taxol", 
            "Breast cancer with brain metastases"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "link": {
            "description": "Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203732"
        }, 
        "location": [
            {
                "contact": {
                    "email": "laurel.chadde@northwestern.edu", 
                    "last_name": "Laurel R Chadde", 
                    "phone": "312-695-1371"
                }, 
                "contact_backup": {
                    "email": "leanne.fountas@northwestern.edu", 
                    "last_name": "Leanne Fountas", 
                    "phone": "312-695-1342"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Priya Kumthekar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "csmith@gabrailcancercenter.com", 
                    "last_name": "Carrie Smith, RN", 
                    "phone": "330-492-3345"
                }, 
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44718"
                    }, 
                    "name": "Gabrail Cancer Center Research"
                }, 
                "investigator": {
                    "last_name": "Nashat Y Gabrail, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nolesc@uthscsa.edu", 
                    "last_name": "Cherie Noles", 
                    "phone": "210-450-5964"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Univeristy of Texas Health Science Center in San Antonio"
                }, 
                "investigator": {
                    "last_name": "Andrew Brenner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER2+ Breast Cancer Patients With Progressive/Recurrent Brain Metastases", 
        "overall_contact": {
            "email": "vburdusel@angiochem.com", 
            "last_name": "Veronica Burdusel, M.Sc. Pharm.", 
            "phone": "514-788-7800", 
            "phone_ext": "206"
        }, 
        "overall_contact_backup": {
            "email": "blawrence@angiochem.com", 
            "last_name": "Betty Lawrence", 
            "phone": "514-788-7800", 
            "phone_ext": "205"
        }, 
        "overall_official": {
            "affiliation": "Angiochem Inc", 
            "last_name": "Jean-Paul Castaigne, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Intracranial objective response rate", 
            "safety_issue": "No", 
            "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048059"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of intracranial objective response", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "measure": "Median intracranial progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "measure": "Intracranial PFS rates at 3, 6 and 12 months", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "measure": "6-month overall survival rate", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled"
            }, 
            {
                "measure": "Extracranial ORR", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled"
            }, 
            {
                "measure": "Number of Patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled"
            }, 
            {
                "description": "To determine the drug concentration and distribution in the plasma. (AUC, Cmax, T1/2)", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "On Day 1 of Cycles 1 and 3"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }
        ], 
        "source": "Angiochem Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Angiochem Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}